Opendata, web and dolomites

VOGAS SIGNED

Screening of Gastric Cancer via Breath volatile organic compounds by Hybrid Sensing Approach

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 VOGAS project word cloud

Explore the words cloud of the VOGAS project. It provides you a very rough idea of what is the project "VOGAS" about.

panels    tissue    human    enrolled    stage    electronic    pylori    brazil    screening    ukraine    prototypes    coupled    spectrometry    countries    vital    atrophy    ms    previously    utilizing    metaplasia    building    breath    american    composition    individuals    detecting    dysplasia    gold    bacterial    analyser    precancerous    acquired    organic    nose    compounds    chances    mid    compact    sensors    metal    orthogonal    origin    patients    vocs    diagnosed    components    latin    confounding    flora    chromatography    gastric    spectroscopic    cured    lesions    mechanisms    disease    gas    combine    international    america    obtaining    oxide    exhaled    intestinal    expertise    voc    infrared    lines    competences    geographical    nanoparticles    chile    volatile    cancer    colombia    portable    concentration    eastern    mass    latvia    infection    invasive    clinical    device    headspace    tool    good    parallel    members    collaborations    gc    schemes    dimensional    cell    lack    techniques    data    burden    first    validated    optimized    analytical   

Project "VOGAS" data sheet

The following table provides information about the project.

Coordinator
TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY 

Organization address
address: SENATE BUILDING TECHNION CITY
city: HAIFA
postcode: 32000
website: www.technion.ac.il

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 3˙781˙179 €
 EC max contribution 3˙781˙179 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2018-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2021-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY IL (HAIFA) coordinator 650˙363.00
2    LATVIJAS UNIVERSITATE LV (RIGA) participant 510˙000.00
3    UNIVERSITAET INNSBRUCK AT (INNSBRUCK) participant 395˙535.00
4    UNIVERSITAET ULM DE (ULM) participant 385˙000.00
5    JLM INNOVATION GMBH DE (TUEBINGEN) participant 375˙000.00
6    Teknologian tutkimuskeskus VTT Oy FI (Espoo) participant 358˙875.00
7    UPPSALA UNIVERSITET SE (UPPSALA) participant 253˙727.00
8    UNIVERSIDAD DE PAMPLONA CO (PAMPLONA) participant 250˙625.00
9    NATIONAL CANCER INSTITUTE UA (KIYV) participant 210˙000.00
10    HOSPITAL UNIVERSITARIO SAN IGNACIO CO (BOGOTA) participant 209˙984.00
11    PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE CL (SANTIAGO) participant 182˙068.00
12    FUNDACAO ANTONIO PRUDENTE BR (SAO PAULO) participant 0.00

Map

 Project objective

Gastric cancer has good chances to be cured if diagnosed at an early stage; currently, there is lack of a reliable non-invasive screening tool. Eastern Europe and Latin America are among the geographical areas with high burden of the disease.

This project is aiming at developing a non-invasive gastric cancer screening tool by detecting characteristic panels of volatile organic compounds (VOCs). The mechanisms of VOC origin and their composition in gastric cancer patients will be addressed via headspace analysis of cancer tissue, cell-lines, and bacterial flora; VOCs identified during this analysis will be compared to the compounds present in human breath, both via gas chromatography coupled to mass spectrometry (GC-MS).

Based on this data, a new type of breath analyser will be developed and validated building upon previously acquired expertise of the consortium members. Specifically, the exhaled breath analyser will combine electronic nose concepts utilizing gold nanoparticles and metal oxide sensors with orthogonal mid-infrared spectroscopic techniques for obtaining multi-dimensional analytical data sets; furthermore, compact pre-concentration schemes will be evaluated. All components will be integrated into several prototypes of portable and optimized devices.

The clinical studies will be conducted in parallel in European (Latvia, Ukraine) and Latin American (Colombia, Brazil, Chile) countries with high disease burden. Patients with gastric cancer and individuals with and without precancerous lesions (dysplasia, atrophy, intestinal metaplasia) will be enrolled. The role of confounding factors including H.pylori infection will be addressed.

As the main result, we expect to provide the first reliable non-invasive gastric cancer screening device based on exhaled breath analysis concepts for future large-scale implementation. The development of according research competences and international collaborations therefore is the most vital component of this project.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VOGAS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VOGAS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More